高级检索
    许锐, 何嘉发, 邹佳晨. 阿贝西利联合内分泌治疗应用于HR+/HER2-、淋巴结阳性、高风险早期乳腺癌：评monarchE研究[J]. 循证医学, 2023, 23(2): 74-77. DOI: 10.12019/j.issn.1671-5144.2023.02.002
    引用本文: 许锐, 何嘉发, 邹佳晨. 阿贝西利联合内分泌治疗应用于HR+/HER2-、淋巴结阳性、高风险早期乳腺癌：评monarchE研究[J]. 循证医学, 2023, 23(2): 74-77. DOI: 10.12019/j.issn.1671-5144.2023.02.002
    shu
    XU Rui, HE Jia-fa, ZOU Jia-chen. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+/HER2-, Node-Positive, High-Risk, Early Breast Cancer: Review of monarchE Study[J]. Journal of Evidence-Based Medicine, 2023, 23(2): 74-77. DOI: 10.12019/j.issn.1671-5144.2023.02.002
    Citation: XU Rui, HE Jia-fa, ZOU Jia-chen. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+/HER2-, Node-Positive, High-Risk, Early Breast Cancer: Review of monarchE Study[J]. Journal of Evidence-Based Medicine, 2023, 23(2): 74-77. DOI: 10.12019/j.issn.1671-5144.2023.02.002
    shu

    阿贝西利联合内分泌治疗应用于HR+/HER2-、淋巴结阳性、高风险早期乳腺癌：评monarchE研究

    Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+/HER2-, Node-Positive, High-Risk, Early Breast Cancer: Review of monarchE Study

      摘要
      • HTML全文
      • 参考文献(6)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回